Results 61 to 70 of about 366,991 (303)

Dimethyl fumarate combined with cisplatin at subcytotoxic doses sensitizes cervical cancer toward ferroptosis and apoptosis through GSH restriction and p53 (re)activation

Molecular Oncology, EarlyView.
Dimethyl fumarate (DMF) reduces growth of HPV‐positive cervical cancer spheroids and induces ferroptosis in cervical cancer cells via blocking SLC7A11/Glutathione (GSH) axis. Combination of subcytotoxic doses of DMF and cisplatin (CDDP) further suppresses spheroid growth and drives cell death in 2D culture models.
Carolina Punziano, Giuseppina Minopoli, Simona Romano, Laura Marrone, Katia Aquilano, Maria Lina Tornesello, Raffaella Faraonio   +6 more
wiley   +1 more source

A low-dose pemetrexed-cisplatin combination regimen induces significant nephrotoxicity in mice

BMC Nephrology
Background Pemetrexed is combined with cisplatin to treat cancer. Whether pemetrexed-cisplatin combination chemotherapy exacerbates cisplatin nephrotoxicity is unclear.
Samson A. Iwhiwhu, Ravi Kumar, Abdul H. Khan, Jeremiah M. Afolabi, Jada D. Williams, Julia E. de la Cruz, Adebowale Adebiyi   +6 more
doaj   +1 more source

ROS-Induced SIRT2 Upregulation Contributes to Cisplatin Sensitivity in Ovarian Cancer

Antioxidants, 2020
Cisplatin resistance remains a significant obstacle for improving the clinical outcome of ovarian cancer patients. Recent studies have demonstrated that cisplatin is an important inducer of intracellullar reactive oxygen species (ROS), triggering cancer ...
Wenyu Wang, Jihye Im, Soochi Kim, Suin Jang, Youngjin Han, Kyung-Min Yang, Seong-Jin Kim, Danny N. Dhanasekaran, Yong Sang Song   +8 more
doaj   +1 more source

Cycloaurated GoId (III) complexes- Possible alternatives to cisplatin? [PDF]

, 2009
The serendipitous discovery of the anti-tumour activity of cisplatin [cis-PtCI₂(NH₃)₂] in 1969 has led to increased interest in the development of new metal-based anti-cancer drugs.
Henderson, William, Kilpin, Kelly Joan
core   +1 more source

Autophagy and urothelial carcinoma of the bladder: A review. [PDF]

, 2016
The incidence of urothelial carcinoma of the urinary bladder (bladder cancer) remains high. While other solid organ malignancies have seen significant improvement in morbidity and mortality, there has been little change in bladder cancer mortality in the
Chandrasekar, Thenappan, Evans, Christopher P   +1 more
core   +2 more sources

Targeted modulation of IGFL2‐AS1 reveals its translational potential in cervical adenocarcinoma

Molecular Oncology, EarlyView.
Cervical adenocarcinoma patients face worse outcomes than squamous cell carcinoma counterparts despite similar treatment. The identification of IGFL2‐AS1's differential expression provides a molecular basis for distinguishing these histotypes, paving the way for personalized therapies and improved survival in vulnerable populations globally.
Ricardo Cesar Cintra, Lucca Paolo Hsu Helmich, Daniel Rodrigues de Bastos, Laura Sichero, Patrícia Savio de Araujo‐Souza, Fabio Passetti, Luisa Lina Villa   +6 more
wiley   +1 more source

Quantification of Cisplatin Encapsulated in Nanomedicine: An Overview

Biosensors
Cisplatin, which kills cancer cells mainly through DNA crosslinking, has been widely used as a first-line chemotherapeutic agent although it also causes severe side effects.
Ziwen Zhang, Jiayu Chen, Tao Wen, Hong Deng, Yiyi Zhang, Hua Guo, Hui Chang, Haiyan Xu, Weiqi Zhang   +8 more
doaj   +1 more source

Deriving chemosensitivity from cell lines: Forensic bioinformatics and reproducible research in high-throughput biology

, 2010
High-throughput biological assays such as microarrays let us ask very detailed questions about how diseases operate, and promise to let us personalize therapy.
Baggerly, Keith A., Coombes, Kevin R.
core   +1 more source

Diazido mixed-amine platinum(IV) anticancer complexes activatable by visible-light form novel DNA adducts [PDF]

, 2013
Platinum diam(m)ine complexes, such as cisplatin, are successful anticancer drugs, but suffer from problems of resistance and side-effects. Photoactivatable PtIV prodrugs offer the potential of targeted drug release and new mechanisms of action.
Bancroft, Brabec, Brabec, Brabec, Butler, Caradonna, Coluccia, Dhara, Eastman, Eastman, Farrell, Farrer, Farrer, Fichtinger-Schepman, Guddneppanavar, Hall, Hamers, Harper, Intini, Jamieson, Kasparkova, Kasparkova, Kauffman, Keck, Kelland, Lau, Lemaire, Mackay, Mackay, Mackay, Najajreh, Ohndorf, O’Dwyer, Pantoja, Phillips, Pracharova, Pregosin, Prokop, Reedijk, Ronconi, Salassa, Salassa, Salassa, Salassa, Siddik, Stehlíková, Still, Suchánková, Tai, Vinje, Vlček, Wang, Westendorf, Westendorf, Westendorf, Wong, Yao, Zenker   +57 more
core   +1 more source

Engineered extracellular vesicles enriched with the miR‐214/199a cluster enhance the efficacy of chemotherapy in ovarian cancer

Molecular Oncology, EarlyView.
Loss of the miR‐214/199a cluster is associated with recurrence in ovarian cancer. Engineered small extracellular vesicles (m214‐sEVs) elevate miR‐214‐3p/miR‐199a‐5p in tumor cells, suppress β‐catenin, TLR4, and YKT6 signaling, reprogram tumor‐derived sEV cargo, reduce chemoresistance and migration, and enhance carboplatin efficacy and survival in ...
Weida Wang, Ayesha Alvero, Yi Qin, Mingjin Wang, Alexandra Fox, Yanfeng Li, Michael Millman, Amy Kemper, Gil Mor, Xian Shuang Liu, Michael Chopp, Zheng Gang Zhang, Yi Zhang   +12 more
wiley   +1 more source